Literature DB >> 32740319

Influence of Asymptomatic Carriers With COVID-19 on Transplantation Resumption in Wuhan.

Xiaoen Bian1, Xiaoli Fan, Yanfeng Wang.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32740319      PMCID: PMC7373358          DOI: 10.1097/TP.0000000000003356

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


× No keyword cloud information.
Wuhan is not only the first city to experience COVID-19 but is also among the first to emerge from the pandemic and currently has only 5 confirmed cases. The existence of asymptomatic carriers poses a threat for disease resurgence and also for virus transmission through transplantation. There are 2 types of asymptomatic carrier: the first is a recessive infection, with persistent but asymptomatic viral detection over 14 days or more, but with a relatively low-infectivity risk in the general community and unknown infection transmission risk from organ donation. The second group of asymptomatic cases are in the early stages of the incubation of the disease and become symptomatic over time but are contagious in the asymptomatic phase. To identify all asymptomatic carriers, Wuhan has carried out SARS-CoV-2 nucleic acid tests (NAT) for all city dwellers since May 14. As of May 24, 6 574 093 NAT tests have been completed, with a total of 227 new asymptomatic carriers and 1 new confirmed case[1]. The asymptomatic infection rate in Wuhan has dropped from 0.5 per 1000 people[2] to 0.03 per 1000 people. The outbreak of COVID-19 greatly slowed and then stopped organ donation and transplantation in Wuhan, but the decrease in the number of infections has allowed hospitals in Wuhan to carefully resume deceased donor organ donation and transplantation. Hyo-Lim Hong et al[3] and Stephen Lagana et al[4] have reported 2 cases of donor-derived transmission of COVID-19, therefore a strategy is needed to prevent donor-derived transmission from all potential asymptomatic carriers. Due to the superficial understanding of COVID-19 and presence of asymptomatic infection in Wuhan, we instituted a protocol to prevent organ donor transmission of COVID-19. Before transplantation both deceased donors and potential recipients undergo SARS-CoV-2 NAT and antibody tests as well as CT scans, which are repeated twice, to avoid the known false negative rates of single tests in COVID-19 patients and detect patients in the early stages of developing symptomatic disease. Donors and recipients must test negative twice to be eligible for transplant. To minimize transmission caused by asymptomatic carriers, potential deceased donors are quarantined in intensive care for >7 days while being tested. Suspected or confirmed COVID-19 patients would be eliminated from the donation process. From April 8, when Wuhan was reopened, to May 25, 43 cases of organ donation after brain death and 125 cases of organ transplant have been completed in Wuhan hospitals. There have been no cases of COVID-19 detected among organ transplant donors and recipients. This protocol may serve as a complex but necessary learning model for others.
  2 in total

1.  Is it Safe to Be Transplanted From Living Donors Who Recovered From COVID-19? Experience of 31 Kidney Transplants in a Multicenter Cohort Study From India.

Authors:  Vivek B Kute; Suraj Godara; Sandeep Guleria; Deepak S Ray; Feroz Aziz; Umapati Hegde; Ashish Sharma; K S Nayak; Vishwanath Siddini; Piyali Sarkar; Sharmila Thukral; Rabi Ranjan Sow Mondal; Jitendra Goswami; Himanshu V Patel; Abi Abraham M; Vivek Pathak; Urmila Anandh; Pranaw Kumar Jha; Suhas Bavikar; Ravi Shankar Bonu; Sanjeev Gulati; Anil Kumar B T; Dinesh Kumar Yadav
Journal:  Transplantation       Date:  2021-04-01       Impact factor: 5.385

2.  Resuming post living donor liver transplantation in the COVID-19 pandemic: real-life experience, single-center experience.

Authors:  Abeer Awad Abdellatif; Mohamad Sherif Mogawer; Mostafa El-Shazli; Hanaa El-Karaksy; Ayman Salah; Amany Abdel-Maqsod; Mona El-Amir; Mohamed Said; Naglaa Zayed; Karim Hosny; Hadeel Gamal Eldeen; Ayman M A Osman; Doaa A Mansour; Ahmed Nabil; Ahmed Abdel-Ghani; Engy A Mogahed; Noha A Yasin
Journal:  Egypt Liver J       Date:  2021-12-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.